Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis
Public ClinicalTrials.gov record NCT01262001. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of FG-3019 in Subjects With Idiopathic Pulmonary Fibrosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To evaluate the safety and tolerability of FG-3019 in subjects with Idiopathic Pulmonary Fibrosis (IPF) and the efficacy of FG-3019 for attenuating fibrosis in these subjects.
Study identification
- NCT ID
- NCT01262001
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 90 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 35 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2011 (Type not available)
- Primary completion
- Jun 26, 2014 (Actual)
- Completion
- Jun 21, 2017 (Actual)
- Last update posted
- Oct 9, 2019
2011 – 2017
United States locations
- U.S. sites
- 18
- U.S. states
- 17
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham Hospital | Birmingham | Alabama | 35294 | — |
| Arizona Pulmonary Specialists, LTD | Scottsdale | Arizona | 85258 | — |
| Yale University | New Haven | Connecticut | 06520 | — |
| Central Florida Pulmonary Group, PA | Orlando | Florida | 32803 | — |
| Tampa General Hospital | Tampa | Florida | 33606 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| Via Christi Hospitals Wichita, Inc. | Wichita | Kansas | 67208 | — |
| University of Louisville | Louisville | Kentucky | 40202 | — |
| St. Luke's Hospital | Chesterfield | Missouri | 63017 | — |
| Rutgers-Robert Wood Johnson Medical School | New Brunswick | New Jersey | 08901 | — |
| Mount Sinai | New York | New York | 10029 | — |
| The Ohio State University | Columbus | Ohio | 43221 | — |
| Vanderbilt University | Nashville | Tennessee | 37232 | — |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75390 | — |
| University of Utah - Lung Health Research | Salt Lake City | Utah | 84108 | — |
| Vermont Lung Center | Colchester | Vermont | 05446 | — |
| Inova Fairfax Hospital | Falls Church | Virginia | 22042 | — |
| University of Wisconsin School of Medicine & Public Health | Madison | Wisconsin | 53705 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01262001, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 9, 2019 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01262001 live on ClinicalTrials.gov.